The Novartis Malaria Initiative

Primary tabs

The Novartis Malaria Initiative

For over a decade, the Novartis Malaria Initiative has been a pioneer in the fight against malaria. Focused on access, treatment, R&D and capacity building, the initiative is the largest access-to-medicine program within Novartis measured by the number of patients reached annually. Together with our partners, and with our continued patient-centric approach, we are committed to the common goal of malaria elimination.

Content from this campaign

Novartis Renews Commitment to Malaria Elimination, Investing USD 100 Million to Research and Develop Next-generation Antimalarials
Company to invest more than USD 100 million to advance research and development of new antimalarials over the next five years Commitment includes expanding access to pediatric antimalarials and implementing capacity-building programs to contribute to the WHO’s target of reducing malaria-related child mortality by at least 90% by 2030 New opinion...
Apr 17, 2018 1:20 AM ET
Novartis and Medicines for Malaria Venture Launch Patient Trial in Africa for KAF156, a Novel Compound Against Multidrug-resistant Malaria
Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection, including resistant strains, and blocking parasite transmission KAF156 is first compound from the imidazolopiperazines, a novel class of antimalarials, to enter phase IIb combination studies Clinical trial has started early...
Aug 21, 2017 9:20 AM ET
Novartis Story About the Rising Concern of Malaria That Resists Treatment
In Kenya, about three-quarters of the population is at risk for malaria, and all four species of the malaria parasite that infect humans occur in the country. Although there has been substantial progress, malaria remains the leading cause of mortality in Kenya, killing an estimated 30,000 people every year, most of them children under 5 years old. Lake Victoria in southwestern Kenya is...
Aug 18, 2017 6:40 PM ET
Malaria Fighter Rides Bicycle into Battle with Disease, Story from Novartis
Healthcare worker Dismus Mwalukwanda is on the front line of the battle against malaria. Saving lives is his priority ...
Aug 18, 2017 12:50 PM ET
Novartis Story Celebrates a Life Dedicated to Fighting Malaria
In Kenya, about three-quarters of the population is at risk for malaria, and all four species of the malaria parasite that infect humans occur in the country. Although there has been substantial progress, malaria remains the leading cause of mortality in Kenya, killing an estimated 30,000 people every year, most of them children under 5 years old. Lake Victoria in southwestern Kenya is...
Aug 14, 2017 10:45 AM ET

Pages